โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

Secukinumab Open Label Roll-over Extension Protocol

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...

Current Status

Recruiting

Auto-verified from ClinicalTrials.gov

Verified Dec 22, 2025

Phase

Clinical Trial

Sponsor

Novartis Pharmaceuticals

Enrollment Target

715

Start Date

Dec 2020

๐Ÿ“Š
1 of 715 participants interested
0% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.

Who Can Participate

Inclusion Criteria

Signed informed consent must be obtained for adult participants before any assessment is performed. Written informed assent and parental permission (age as per local law) must be obtained for pediatric participants before any assessment is performed. If participants reach age of consent (age as per local law) during the study, they will need to also sign the corresponding study informed consent(s). 2. Ability to communicate effectively with the investigator, to understand and willing to comply with the requirements of the study. 3. Participant has completed treatment per protocol in a Novartis study of secukinumab (unless otherwise specified in a parent study protocol). Participants, who derive benefit from the treatment with secukinumab but have not completed the treatment in certain parent studies, due to parent study termination by Novartis, may be eligible if the termination was due to reasons other than safety or lack of efficacy (technical / administrative

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

715 participants

๐ŸŽ‚

Age Range

6 Years - 100 Years

โšง

Gender

ALL

๐Ÿข

Sponsor

Novartis Pharmaceuticals

Study Locations

Choose your preferred location or select flexible during enrollment

COMPLETED

Fullerton

California

Location available
View Fullerton location page
COMPLETED

La Mesa

California

Location available
View La Mesa location page
COMPLETED

San Leandro

California

Location available
View San Leandro location page
COMPLETED

Santa Monica

California

Location available
View Santa Monica location page
COMPLETED

Upland

California

Location available
View Upland location page
COMPLETED

Van Nuys

California

Location available
View Van Nuys location page
COMPLETED

West Hills

California

Location available
View West Hills location page
COMPLETED

Denver

Colorado

Location available
View Denver location page
RECRUITING

Boca Raton

Florida

Location available
View Boca Raton location page

๐Ÿ“ And 19 more locations available

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Find More Multiple Myeloma Trials by City

Browse all multiple myeloma clinical trials in these cities โ€” not just this study.

Looking for Based on the limited information provided, this appears to be an extension study for secukinumab, but the primary medical condition is not clearly stated in the given data. Secukinumab is commonly used to treat: Psoriasis Treatment in Fullerton?

Join others in California exploring innovative treatment options through clinical research

Based on the limited information provided, this appears to be an extension study for secukinumab, but the primary medical condition is not clearly stated in the given data. Secukinumab is commonly used to treat: Psoriasis Treatment Options in Fullerton, California

If you're searching for Based on the limited information provided, this appears to be an extension study for secukinumab, but the primary medical condition is not clearly stated in the given data. Secukinumab is commonly used to treat: Psoriasis treatment in Fullerton, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Fullerton, La Mesa, San Leandro and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Based on the limited information provided, this appears to be an extension study for secukinumab, but the primary medical condition is not clearly stated in the given data. Secukinumab is commonly used to treat: Psoriasis. All study-related care is provided at no cost to participants.

Local Sites
3 locations in California
Now Enrolling
Up to 715 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Based on the limited information provided, this appears to be an extension study for secukinumab, but the primary medical condition is not clearly stated in the given data. Secukinumab is commonly used to treat: Psoriasis?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for Based on the limited information provided, this appears to be an extension study for secukinumab, but the primary medical condition is not clearly stated in the given data. Secukinumab is commonly used to treat: Psoriasis

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This Based on the limited information provided, this appears to be an extension study for secukinumab, but the primary medical condition is not clearly stated in the given data. Secukinumab is commonly used to treat: Psoriasis Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT04638647. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.